Search

Your search keyword '"Saltzman, Joel N."' showing total 20 results

Search Constraints

Start Over You searched for: Author "Saltzman, Joel N." Remove constraint Author: "Saltzman, Joel N." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
20 results on '"Saltzman, Joel N."'

Search Results

2. Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

3. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

4. Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery

5. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014

7. Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC).

8. Impact of facility type, insurance status, and income on use of single agent chemotherapy (SACT) for advanced hepatocellular carcinoma (AHCC): Analysis of National Cancer Database (NCDB).

9. Primary liver angiosarcoma and factors associated with improved outcomes: An analysis of the National Cancer Database.

10. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

13. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)

15. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203)

16. HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC).

17. E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).

18. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study.

19. Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.

20. The effects of integrating an advanced practice palliative care nurse in a community oncology center: a pilot study.

Catalog

Books, media, physical & digital resources